MIRUM PHARMACEUTICALS, INC.
7.60%
3,735,220
1759425
604749101
Aug 17, 2025
Aug 20, 2025, 05:17 PM
Reporting Persons (20)
This is a joint filing. The reported shares may overlap between reporting persons and should not be summed.
| Name | Type | % of Class | Aggregate | Sole Voting | Shared Voting |
|---|---|---|---|---|---|
| Patrick J. Heron | Individual | 7.60% | 3,735,220 | 82,482 | 3,735,220 |
| James N. Topper | Individual | 7.40% | 3,735,220 | 0 | 3,735,220 |
| Frazier Life Sciences IX, L.P. | Partnership | 7.10% | 3,566,912 | 0 | 3,566,912 |
| FHMLS IX, L.P. | Partnership | 7.10% | 3,566,912 | 0 | 3,566,912 |
| FHMLS IX, L.L.C. | Other | 7.10% | 3,566,912 | 0 | 3,566,912 |
| FHMLSP, L.P. | Partnership | 3.10% | 1,574,374 | 0 | 1,574,374 |
| Frazier Life Sciences Public Fund, L.P. | Partnership | 3.10% | 1,574,374 | 0 | 1,574,374 |
| FHMLSP, L.L.C. | Other | 3.10% | 1,574,374 | 0 | 1,574,374 |
| FHMLSP Overage, L.P. | Partnership | 1.90% | 940,573 | 0 | 940,573 |
| Frazier Life Sciences Public Overage Fund, L.P. | Partnership | 1.90% | 940,573 | 0 | 940,573 |
| FHMLSP Overage, L.L.C. | Other | 1.90% | 940,573 | 0 | 940,573 |
| FHMLS XI, L.L.C. | Other | 1.10% | 544,954 | 0 | 544,954 |
| Frazier Life Sciences XI, L.P. | Partnership | 1.10% | 544,954 | 0 | 544,954 |
| FHMLS XI, L.P. | Partnership | 1.10% | 544,954 | 0 | 544,954 |
| FHMLS X, L.L.C. | Other | 0.30% | 168,308 | 0 | 168,308 |
| FHMLS X, L.P. | Partnership | 0.30% | 168,308 | 0 | 168,308 |
| Frazier Life Sciences X, L.P. | Partnership | 0.30% | 168,308 | 0 | 168,308 |
| Albert Cha | Individual | 0.00% | 0 | 0 | 0 |
| James Brush | Individual | 0.00% | 0 | 0 | 0 |
| Daniel Estes | Individual | 0.00% | 0 | 0 | 0 |
Disclosure Items (3)
Common Stock, par value $0.0001 per share
MIRUM PHARMACEUTICALS, INC.
989 E Hillsdale Blvd., Suite 300, FOSTER CITY, CA, 94404
The information contained in Rows 7, 8, 9, 10, 11, and 13 of each Reporting Person's cover page to this Schedule 13D (including the footnotes thereto) is incorporated by reference into this Item 5. FLSPF directly holds 1,574,374 shares of Common Stock of the Issuer (the "FLSPF Shares"). FHMLSP, L.P. is the general partner of FLSPF and the general partner of FHMLSP, L.P. is FHMLSP, L.L.C., which is managed by an investment committee of four that acts by majority vote. Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLSPF, and this Schedule 13D corrects any previous attribution to, and overstatement of beneficial ownership by, such members as reflected in any prior Statements. FLSPOF directly holds 940,573 shares of Common Stock of the Issuer (the "FLSPOF Shares"). FHMLSP Overage, L.P. is the general partner of FLSPOF and the general partner of FHMLSP Overage, L.P. is FHMLSP Overage, L.L.C., which is managed by an investment committee of four that acts by majority vote. Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLSPOF, and this Schedule 13D corrects any previous attribution to, and overstatement of beneficial ownership by, such members as reflected in any prior Statements. FLS IX directly holds 3,566,912 shares of Common Stock of the Issuer (the "FLS IX Shares"). FHMLS IX, L.P. is the general partner of FLS IX and FHMLS IX, L.L.C. is the general partner of FHMLS IX, L.P. Heron and Topper are the members of FHMLS IX, L.L.C. and therefore share voting and investment power over the FLS IX Shares. FLS X directly holds 168,308 shares of Common Stock of the Issuer (the "FLS X Shares"). FHMLS X, L.P. is the general partner of FLS X and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Heron and Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the FLS X Shares. FLS XI directly holds 544,954 shares of Common Stock of the Issuer (the "FLS XI Shares"). FHMLS XI, L.P. is the general partner of FLS XI and the general partner of FHMLS XI, L.P. is FHMLS XI, L.L.C., which is managed by an investment committee of three that acts by majority vote. Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLS XI, and this Schedule 13D corrects any previous attribution to, and overstatement of beneficial ownership by, such members as reflected in any prior Statements. Except as specifically stated herein, the filing of this Schedule 13D shall not be construed as an admission that any Reporting Person or any of the foregoing is, for the purposes of Section 13(d) and/or Section 13(g) of the Act or otherwise, the beneficial owner of any securities covered by this Schedule 13D or a member of a "group" with any other person.
Exhibit 99.1 Joint Filing Agreement (incorporated by reference to Exhibit A to Schedule 13D/A filed on September 5, 2023)